Amlodipine
- Generic Name
- Amlodipine
- Brand Names
- Amlobenz, Azor, Caduet, Dafiro, Exforge, Exforge Hct, Katerzia, Lotrel, Norliqva, Norvasc, Prestalia, Tribenzor, Twynsta, Viacoram
- Drug Type
- Small Molecule
- Chemical Formula
- C20H25ClN2O5
- CAS Number
- 88150-42-9
- Unique Ingredient Identifier
- 1J444QC288
- Background
Amlodipine, initially approved by the FDA in 1987, is a popular antihypertensive drug belonging to the group of drugs called dihydropyridine calcium channel blockers. Due to their selectivity for the peripheral blood vessels, dihydropyridine calcium channel blockers are associated with a lower incidence of myocardial depression and cardiac conduction abnormalities than other calcium channel blockers .
Amlodipine is commonly used in the treatment of high blood pressure and angina. Amlodipine has antioxidant properties and an ability to enhance the production of nitric oxide (NO), an important vasodilator that decreases blood pressure . The option for single daily dosing of amlodipine is an attractive feature of this drug .
- Indication
Amlodipine may be used alone or in combination with other antihypertensive and antianginal agents for the treatment of the following conditions :
• Hypertension
• Coronary artery disease
• Chronic stable angina
• Vasospastic angina (Prinzmetal’s or Variant angina)
• Angiographically documented coronary artery disease in patients without heart failure or an ejection fraction < 40%
- Associated Conditions
- Cardiovascular Events, Chronic Stable Angina Pectoris, Coronary Artery Disease (CAD), Homozygous Familial Hypercholesterolaemia (HoFH), Hypertension, Hypertension, Essential Hypertension, Mixed Dyslipidemias, Primary Hypercholesterolemia, Vasospastic Angina
- Associated Therapies
- -
Efficacy and Safety of Amlodipine and Losartan in Patients With Essential Hypertension
- Conditions
- First Posted Date
- 2009-07-20
- Last Posted Date
- 2009-07-20
- Lead Sponsor
- Hanmi Pharmaceutical Company Limited
- Target Recruit Count
- 320
- Registration Number
- NCT00942344
- Locations
- 🇰🇷
14 sites in Korea, Seoul, Busan, etc., Korea, Republic of
Efficacy/Safety of Amlodipine Plus Losartan Versus Amlodipine in Patients With Essential Hypertension
- First Posted Date
- 2009-07-16
- Last Posted Date
- 2016-10-12
- Lead Sponsor
- Hanmi Pharmaceutical Company Limited
- Target Recruit Count
- 185
- Registration Number
- NCT00940667
- Locations
- 🇰🇷
13 sites in Korea, Seoul, Busan, etc., Korea, Republic of
A Study to Evaluate the Pharmacokinetic Drug Interaction After Oral Concurrent Administration of Fimasartan and Amlodipine in Healthy Male Volunteers
- First Posted Date
- 2009-07-13
- Last Posted Date
- 2009-10-08
- Lead Sponsor
- Boryung Pharmaceutical Co., Ltd
- Target Recruit Count
- 34
- Registration Number
- NCT00938197
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
Glycemic And Blood Pressure Control In Type 2 Diabetes, In A Primary Care Unit: A Staged Management Strategy
- First Posted Date
- 2009-07-09
- Last Posted Date
- 2011-10-26
- Lead Sponsor
- Hospital de Clinicas de Porto Alegre
- Target Recruit Count
- 124
- Registration Number
- NCT00935805
- Locations
- 🇧🇷
Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil
Study to Evaluate the Bioavailability of the Test Formulation of Amlodipine 10 mg Tablets (Torrent Pharmaceuticals Limited) Compared to a 10 mg Dose of Norvasc® (Pfizer) in 22 Fasted, Healthy Adult Subjects
- Conditions
- First Posted Date
- 2009-07-03
- Last Posted Date
- 2009-07-17
- Lead Sponsor
- Torrent Pharmaceuticals Limited
- Registration Number
- NCT00932763
- Locations
- 🇺🇸
CEDRA Clinical Research, LLC, San Antonio, Texas, United States
Study to Evaluate the Bioavailability of the Test Formulation of Amlodipine 10 mg Tablets (Torrent Pharmaceuticals Limited) Compared to a 10 mg Dose of Norvasc® (Pfizer) in 18 Fed, Healthy Adult Subjects
- Conditions
- First Posted Date
- 2009-07-03
- Last Posted Date
- 2009-07-16
- Lead Sponsor
- Torrent Pharmaceuticals Limited
- Registration Number
- NCT00932880
- Locations
- 🇺🇸
CEDRA Clinical Research, LLC, San Antonio, Texas, United States
The Effects of Renin Angiotensin System Blockage (RAS), Calcium Channel Blocker and Combined Drugs on TWEAK, PTX3 and FMD Levels in Diabetic Proteinuric Patients With Hypertension
- Conditions
- Interventions
- First Posted Date
- 2009-06-16
- Last Posted Date
- 2009-06-17
- Lead Sponsor
- Gulhane School of Medicine
- Target Recruit Count
- 105
- Registration Number
- NCT00921570
- Locations
- 🇹🇷
GATA Nephrology, Ankara, Turkey
Effect of Two Doses of Olmesartan Medoxomil and Amlodipine on Vascular Markers in Hypertensive Patients With Metabolic Syndrome
- Conditions
- Interventions
- First Posted Date
- 2009-05-01
- Last Posted Date
- 2018-12-24
- Target Recruit Count
- 60
- Registration Number
- NCT00891267
Telmisartan and Amlodipine Fixed Dose Combination [FDC] Trial for the Treatment of Severe Hypertension
- Conditions
- Interventions
- First Posted Date
- 2009-03-12
- Last Posted Date
- 2014-05-20
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 858
- Registration Number
- NCT00860262
- Locations
- 🇧🇬
1235.20.008 Boehringer Ingelheim Investigational Site, Sofia, Bulgaria
🇭🇺1235.20.152 Boehringer Ingelheim Investigational Site, Budapest, Hungary
🇷🇴1235.20.254 Boehringer Ingelheim Investigational Site, Iasi, Romania
Efficacy and Safety of Aliskiren Administered in Combination With Amlodipine Versus Amlodipine Alone in African American Patients With Stage 2 Hypertension
- First Posted Date
- 2009-03-02
- Last Posted Date
- 2012-04-30
- Lead Sponsor
- Novartis
- Target Recruit Count
- 443
- Registration Number
- NCT00853957
- Locations
- 🇺🇸
Investigative Site, Milwaukeee, Wisconsin, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.